Center for Genetic Engineering and Biotechnology

{{Short description|State-owned biotechnology institute in Cuba}}

{{Infobox government agency

| name = Center for Genetic Engineering and Biotechnology

| native_name =

| native_name_a =

| native_name_r =

| type = Research institute

| seal =

| seal_size =

| seal_caption =

| seal_alt =

| logo =

| logo_size =

| logo_caption =

| logo_alt =

| image = Visita al Centro de Ingeniería Genética y Biotecnología - 17545422613.jpg

| image_size =

| image_caption = Offices of the CIGB

| image_alt =

| formed = {{Start date|1985|07|01}}

| preceding1 =

| preceding2 =

| dissolved =

| superseding1 =

| superseding2 =

| agency_type =

| jurisdiction = {{CUB}}

| status =

| headquarters = Avenida 31 No. 15802, Havana, Cuba

| coordinates = {{coord|23.0738|-82.4523|display=inline,title}}

| motto =

| employees =

| budget =

| minister_type =

| minister1_name =

| minister1_pfo =

| minister2_name =

| minister2_pfo =

| deputyminister_type =

| deputyminister1_name =

| deputyminister1_pfo =

| deputyminister2_name =

| deputyminister2_pfo =

| chief1_name =

| chief1_position =

| chief2_name =

| chief2_position =

| parent_department =

| parent_agency =

| parent_agency_type =

| child1_agency =

| child2_agency =

| keydocument1 =

| website = {{URL|www.cigb.edu.cu}}

| agency_id =

| map =

| map_size =

| map_caption =

| map_alt =

| footnotes =

| embed =

}}

The Center for Genetic Engineering and Biotechnology ({{langx|es|Centro de Ingeniería Genética y Biotecnología}}, CIGB) is a research institute in Havana, Cuba.

Founding

In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World.{{Rp|page=132}} Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy.{{Rp|page=132}} Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.{{Rp|page=132}}

Activity

In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.{{Cite web |title=UA Health Sciences Researchers Look to Collaborate With Cuba on Diabetic Wound Therapy {{!}} Department of Medicine |url=https://deptmedicine.arizona.edu/news/2016/ua-health-sciences-researchers-look-collaborate-cuba-diabetic-wound-therapy |access-date=2023-12-27 |website=deptmedicine.arizona.edu}} Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.

As of 2017, CIGB had 1,600 employees and sold 21 products internationally.{{Rp|page=138}}

As of 2020, CIGB had two joint ventures with China.{{Cite book |last=Yaffe |first=Helen |title=We Are Cuba! How a Revolutionary People Have Survived in a Post-Soviet World |date=2020 |publisher=Yale University Press |isbn=978-0-300-23003-1 |edition=hardcover |location=USA}}{{Rp|page=143}}

It is responsible for creating the Abdala vaccine.{{Cite web|title=Cuba's COVID vaccine rivals BioNTech-Pfizer, Moderna |date=2021-06-27|url=https://www.dw.com/en/cubas-covid-vaccine-rivals-biontech-pfizer-moderna/a-58052365|access-date=2021-06-28|website=DW.COM|language=en-GB}}{{cite web |title=ABDALA Clinical Study - Phase III |url=https://rpcec.sld.cu/en/trials/RPCEC00000359-En |website=rpcec.sld.cu |publisher=Registro Público Cubano de Ensayos Clínicos |access-date=March 22, 2021 |url-status=live|archive-url=https://web.archive.org/web/20210320062328/https://rpcec.sld.cu/en/trials/RPCEC00000359-En |archive-date=2021-03-20 }}{{cite web |title=ABDALA Clinical Study |url=https://rpcec.sld.cu/en/trials/RPCEC00000346-En |website=rpcec.sld.cu |publisher=Registro Público Cubano de Ensayos Clínicos |access-date=March 22, 2021 |url-status=live|archive-url=https://web.archive.org/web/20210122072416/https://rpcec.sld.cu/en/trials/RPCEC00000346-En |archive-date=2021-01-22 }}

The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.{{cite web |last1=Sánchez |first1=Liz Conde |title=How is Mambisa progressing on the road to authorization as an anti-COVID-19 vaccine? |url=https://en.granma.cu/cuba/2022-04-07/how-is-mambisa-progressing-on-the-road-to-authorization-as-an-anti-covid-19-vaccine |website=en.granma.cu |access-date=6 May 2022 |language=en |date=7 April 2022}}

See also

References

{{reflist}}